A collaboration between Jiva.ai and Aevice Health has developed a predictive model that identifies potential asthma exacerbations up to 72 hours in advance.
RT’s Three Key Takeaways:
- Predictive Accuracy: The Ai-powered method predicts asthma exacerbations with more than 60% accuracy using data from wearable monitors and patient inputs.
- Multimodal Data Integration: The system combines continuous respiratory data from a wireless stethoscope with patient-reported symptoms to analyze physiological trends.
- Early Warning Windows: The partnership established a framework that identifies risks within 24-, 48-, and 72-hour windows, allowing for proactive clinical intervention.
Jiva.ai and Aevice Health have completed a three-year innovation program to develop an artificial intelligence method for predicting asthma exacerbations before they occur, according to a news release.
Funded by Innovate UK and Enterprise Singapore, the co-innovation program built medical Ai that predicts asthma exacerbations with more than 60% accuracy. By combining advanced Ai capabilities with expertise in remote patient monitoring, the partnership delivered a predictive tool designed to help patients proactively manage their respiratory healthcare.
The project integrated continuous respiratory monitoring data with patented model-fusion Ai technology, allowing multiple streams of physiological and patient-reported data to be analyzed together. The system uses the AeviceMD, a Food and Drug Administration (FDA) cleared wireless stethoscope and software platform that tracks real-time respiratory data. During testing, the device streamed data including wheeze detection, heart rate, and respiratory rate alongside patient app inputs. This multimodal data was then processed through the Jiva Ai platform.
The partnership established a compliant international data-sharing framework and analyzed anonymized data from 185 patients across multiple clinical sites. These integrated models demonstrated the ability to predict sudden asthma exacerbations within distinct 24-, 48-, and 72-hour windows, providing patients with a quantitative warning system to take early action according to their clinical plan.
Chronic Respiratory Disease (CRD) affects more than 545 million people worldwide and is one of the leading causes of death, according to the news release. Asthma and chronic obstructive pulmonary disease (COPD) are the two most common forms of CRD, which can be worsened by stress, infections, allergens, and poor air quality.
“This partnership harnessed the best of Aevice Health and Jiva.ai: they brought the novelty of capturing the data in the first place, and we brought along the expert ability to analyse it,” said Manish Patel, chief executive officer and co-founder of Jiva.ai, in a news release. Following the completion of the program, the companies are exploring the next phase of clinical validation and regulatory development to advance the technology toward commercial deployment.
“Developing a predictive model for asthma exacerbations is an important step toward helping patients better understand their risk and stay engaged with their care,” said Rex Tan, chief technology officer at Aevice Health. “By identifying individuals at higher risk of deterioration, this approach can support earlier intervention, better adherence, and more proactive disease management.”
